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Abstract
Background and Objectives Considering the clinical and
economic burden of biological drugs in cancer treatment, it
is necessary to explore how these drugs are used in routine
care in Italy and how they affect the sustainability of the
National Health Services. This study aimed to investigate
the prevalence of use and costs of biological drugs for
cancer treatment in a general population of Southern Italy
in the years 2010–2014.
Methods This was a retrospective, observational study
using data from the healthcare administrative databases of
Messina Province for the years 2010–2014. In this study,
users of biological drugs for cancer treatment were char-
acterized and the prevalence of use and costs were calcu-
lated over time. The potential impact of biosimilars on the
expenditure was also estimated.
Results Of a population of 653,810 residents in the Mes-
sina area during the study years, 2491 (0.4%) patients
received at least one study drug. The most frequently used
were monoclonal antibodies (mAbs) (n = 1607; 64.5%)
and tyrosine kinase inhibitors (TKIs) (n = 609; 24.4%).
mAbs were mainly used by females (60.3%) for metastasis
due to an unspecified primary tumor, lymphomas, or breast
cancer (24.2, 16.7, and 13.7%, respectively). Most users of
small molecules were males (56.3%) being treated for
multiple myeloma, metastasis due to unspecified primary
tumor, leukemia, and lung cancer (13.1, 12.6, 9.5, and
8.9%, respectively). During the study years, the prevalence
of use doubled from 0.9 to 1.8 per 1000 inhabitants; like-
wise, the related expenditure grew from €6.6 to €13.6
million. Based on our forecasts, this expenditure will grow
to €25 million in 2020. Assuming a 50% biosimilar uptake
(trastuzumab and rituximab), a potential yearly saving of
almost €1 million may be achieved.
Conclusions In recent years, the use and costs of biological
drugs in cancer patients have increased dramatically in a
large population from Southern Italy. This trend may be
counterbalanced by adopting biosimilars once they are
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available. Claims databases represent a valid tool to mon-
itor the uptake of newly marketed biological drugs and
biosimilars.
Key Points
In recent years, the use of biological drugs for cancer
treatment has increased rapidly and the
corresponding costs almost doubled from €6.6 to
€13.6 million.
Based on our forecasts, this expenditure will grow to
€25 million in 2020 and the use of biosimilars may
provide an annual savings of around €1 million.
Claims databases may represent a valid tool for
monitoring the uptake of newly marketed biological
drugs and biosimilars.
1 Introduction
Biological drugs contain one or more active substances that
may be produced or extracted from a biological system or
through biotechnological procedures [1, 2]. In recent years,
biological drugs have dramatically changed the pharma-
cological management of several high-burden diseases
including specific cancer types. Most of the recently mar-
keted drugs in oncology are monoclonal antibodies (mAbs)
and tyrosine kinase inhibitors (TKIs), which are highly
innovative as they target specific molecules necessary for
tumor growth and progression [3].
Considering the clinical and economic burden of biolog-
ical drugs in cancer treatment, it is necessary to explore how
these drugs are used in routine care and how they affect the
sustainability of the National Health Services (NHSs). Once
a biological drug loses its patent, the corresponding
biosimilar may enter the market, thus guaranteeing an
average 20–30% lower purchase cost than originators [4]. To
date, the only biosimilar that has been approved by the
European Medicines Agency (EMA) for cancer treatment is
rituximab (2017), while trastuzumab and bevacizumab
biosimilars are still currently under review [5].
The marketing of biosimilars may represent a great
opportunity for saving money [6], and post-marketing
monitoring systems using real-world data may be helpful
for the assessment of their impact in clinical practice.
The aim of this retrospective, observational study was to
analyze the use and costs of biologic drugs for cancer
treatment in a large area of Southern Italy in the years
2010–2014. In addition, possible economic savings due to
the marketing of biosimilars for cancer treatment in future
years was estimated.
2 Methods
2.1 Data Source
This retrospective, observational study was conducted
using data extracted from the healthcare administrative
databases of the Messina Local Health Unit, ‘‘G. Martino’’
Hospital, and Papardo Hospital during the years
2010–2014 (from 2011 to 2014 for Papardo Hospital).
Each of these centers provided information on the total use
of biological drugs for cancer treatment from all residents
in Messina Province (Southern Italy).
In each center, specific databases collect anonymous
data related to all the drugs that are reimbursed by the NHS
and dispensed to both inpatients and outpatients. Data on
drugs dispensed to inpatients are recorded by the specific
ward as aggregate data (not at individual level), and were
therefore not used for this study. In outpatients, systemic
biological drugs administered as subcutaneous injections or
orally are dispensed by the hospital pharmacists to the
patient, who will self-administer the drug. Systemic bio-
logical drugs administered as an intravenous infusion are
administered exclusively in the hospital setting, even to
outpatients. However, the dispensing of biological drugs to
outpatients is recorded at patient level through the dis-
pensing database, which is routinely populated by the
hospital pharmacy. This database includes data about the
dispensed drug (i.e., market authorization code, brand
name, Anatomical Therapeutic Chemical [ATC] classifi-
cation system code, number of dispensed packages), the
patient (date of birth, sex, citizenship, potential co-payment
exemption codes), date of dispensing, and costs.
Each of the three centers has its own dispensing data
flow, which is independent from that of the other centers.
Furthermore, dispensing databases are generated for
administrative reasons, and they routinely undergo quality
checks in order to avoid duplicates. Users of the study
drugs were identified and assigned an anonymous and
unique identifier, thanks to which data from other claims
databases including hospital discharge diagnoses were able
to be linked.
Claims databases containing hospital discharge diagno-
sis are coded using the International Classification of
Diseases, 9th revision, Clinical Modification (ICD9-CM).
2.2 Study Population
All residents in the catchment area of Messina Province
during the years 2010–2014 were considered for this study.
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From this source population, all patients receiving at least
one dispensing of any of the study drugs during the study
period were identified.
2.3 Study Drugs
The biological drugs approved for cancer treatment and
available in Italy during the study years were classified into
mAbs, fusion proteins, immunomodulatory agents, and
small molecules, the latter being further categorized as
TKIs, mammalian target of rapamycin inhibitors (mTOR-
i), and proteasome inhibitors. A complete list of the study
drugs and related indications for use is available in Elec-
tronic Supplementary Materials Table S1.
2.4 Data Analysis
Data on the users of the study drugs were entirely anon-
ymized and pooled. The index date (ID) was identified as
the first date of a study drug being dispensed during the
study years.
As the overall population is dynamic during a calendar
year, the prevalence of the study drugs use was calculated
as the number of study drug users (i.e., patients receiving at
least one study drug during the years 2010–2014) divided
by the estimate of the total number of residents in the
catchment area provided by the National Statistics Office
for each study year, stratified by calendar year and type of
drug. For each calculated prevalence of use, lower and
upper bounds of the corresponding 95% confidence interval
were computed following the Wilson score interval [7]. In
addition, the pharmaceutical expenditure for the study
drugs was measured over time and stratified by type of
biological drug.
Users of different types of biological drug were char-
acterized in terms of age and sex, type of cancer, and
previous use of chemotherapeutics. The type of cancer
was identified based on the last ICD9-CM diagnosis code
of tumor registered in the hospital discharge diagnosis
database within 6 months prior to the ID. Distinction
between a primary (i.e., the original site of the tumor) and
secondary tumor (i.e., any additional sites where the
tumor has spread, also called metastases of primary
tumors) was possible using the specific ICD9-CM codes.
The median number of dispensings per patient was
calculated.
Moreover, costs related to dispensing the study drugs
were calculated over time and the expected expenditure
sustained by public hospitals in the Messina area until 2020
was predicted. Data on the pharmaceutical expenditure for
the study drugs in the years 2015–2016 were provided by
the centers included in this study. Given the available cost-
related information for the years 2010–2016, a linear trend
(which expresses data as a linear function of time) in the
expenditure sustained by the three centers in the Messina
area was estimated (equation: y = 2E ? 06x ? 5E ? 06;
R2 = 0.9966). In particular, it allowed us to determine
whether measurements exhibit an increasing trend that is
statistically distinct from random behavior. Through sta-
tistical extrapolation of data for the years 2017–2020 (in
respect of assumption of a linear trend, independence of
observations, and homoscedasticity), the baseline trend was
calculated (scenario n. 1). Considering the impact of
rituximab and trastuzumab on the yearly expenditure
(35%), we calculated the pharmaceutical expenditure until
2020, assuming that both biosimilar rituximab and trastu-
zumab were 25% cheaper than the corresponding reference
products and hypothesizing an uptake equal to 20, 50, and
80% of the total amount of consumption of the two bio-
logical drugs (scenarios n. 2, 3, and 4, respectively,).
2.5 Ethics Statement
This study was conducted in the context of the ‘‘Progetto
Osservazionale sulla Psoriasi–SOPso’’ project. The study
protocol was notified to the Ethical Committee of the
Academic Hospital of Messina, in agreement with current
national legislation [8]. This study received unconditional
funding from Novartis, which did not interfere in any stage
of the study.
All statistical analyses were conducted using SAS for
Windows, Version 9.3 (SAS Institute, Cary, NC, USA).
Figures were created using Microsoft Office (Microsoft
Corp., Redmond, WA, USA).
3 Results
Overall, of a total population of 653,810 residents in the
catchment of the Messina area during the years 2010–2014,
2491 (0.4%) patients had at least 6 months of database
history and received at least one study drug for cancer
treatment.
The most frequently used drugs were mAbs (n = 1607;
64.5%), followed by TKIs (n = 609; 24.4%) (Table 1).
mAbs were mostly dispensed for the treatment of metas-
tasis due to unspecified primary tumor (24.2%), lym-
phomas (16.7%), breast cancer (13.7%), and colorectal
cancer (9.2%); most mAb users were females (60.3%) and
were 45–64 years old (47.2%). Small molecule users were
more likely to be males (56.3%) and to be slightly older
(65–79 years old; 45.7%), and were receiving the study
drugs mostly due to multiple myeloma, metastasis due to
unspecified primary tumor, leukemia, and lung cancer
(13.1, 12.6, 9.5, and 8.9%, respectively). No users of fusion
proteins or immunomodulatory agents could be identified
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Table 1 Characteristics of users of biological drugs for cancer treatment in the years 2010–2014 in Messina Province
Characteristic mAbs
(n = 1607)
Small molecules Total
(n = 2491)
TKIs
(n = 609)
Proteasome
inhibitors
(n = 203)
mTOR-i
(n = 72)
Total
(n = 884)
Sex
Male 638 (39.7) 382 (62.7) 95 (46.8) 21 (29.2) 498 (56.3) 1136 (45.6)
Female 969 (60.3) 227 (37.3) 108 (53.2) 51 (70.8) 386 (43.7) 1355 (56.4)
Age (years) [median (Q1–Q3)] 62 (53–71) 65 (56–74) 70 (61–77) 63 (54.5–71.5) 67 (58–75) 64 (54–72)
Age categories (years)
\45 158 (9.8) 44 (7.2) 3 (1.5) 4 (5.6) 51 (5.7) 209 (8.4)
45–64 759 (47.2) 246 (40.4) 60 (29.6) 35 (48.6) 341 (38.6) 1100 (44.2)
65–79 589 (36.7) 265 (43.5) 113 (55.7) 26 (36.1) 404 (45.7) 993 (39.9)
C 80 101 (6.3) 54 (8.9) 27 (13.3) 7 (9.7) 88 (10.0) 189 (7.5)
Follow-up (days) [median (Q1–Q3)] 327 (130–595) 313 (91–867) 320 (132–644) 225 (69–358.5) 305 (95.5–777) 319 (119–640)
Number of dispensings of the
biological drug at ID [median
(Q1–Q3)]
7 (3–14) 4 (2–12) 16 (8–25) 3 (1–6) 5 (2–16) 6 (3–14)
Type of cancera
Lymphatic tissueb 268 (16.7) 2 (0.3) 3 (1.5) 5 (0.6) 273 (11.0)
Breast (female) 220 (13.7) 10 (1.6) 4 (5.6) 14 (1.6) 234 (9.4)
Colorectal 148 (9.2) 3 (0.5) 3 (0.3) 151 (6.1)
Leukemia 77 (4.8) 84 (13.8) 84 (9.5) 161 (6.5)
Lung 24 (1.5) 79 (13.0) 79 (8.9) 103 (4.1)
Liver cancer 5 (0.3) 48 (7.9) 48 (5.4) 53 (2.1)
Multiple myeloma 4 (0.2) 116 (57.1) 116 (13.1) 120 (4.8)
Metastasis of unspecified primary
tumor
389 (24.2) 102 (16.7) 1 (0.5) 8 (11.1) 111 (12.6) 500 (20.1)
Other neoplasmc 124 (7.7) 55 (9.0) 14 (6.9) 5 (6.9) 74 (8.4) 198 (7.9)
Previous chemotherapyd
Number of chemotherapeutics
0 916 (57.0) 517 (84.9) 193 (95.1) 34 (47.2) 744 (84.2) 1660 (66.6)
1 220 (13.7) 49 (8.0) 9 (4.4) 34 (47.2) 92 (10.4) 312 (12.5)
2–3 422 (26.3) 42 (6.9) 1 (0.5) 4 (5.6) 47 (5.3) 469 (18.9)
C 4 49 (3.0) 1 (0.2) 1 (0.1) 50 (2.0)
Type of chemotherapeutics
Cyclophosphamide 342 (21.3) 1 (0.2) 1 (0.5) 2 (0.2) 344 (13.8)
Fluorouracil 234 (14.6) 1 (0.2) 1 (1.4) 2 (0.2) 236 (9.5)
Doxorubicin 153 (9.5) 7 (3.9) 4 (5.6) 11 (1.2) 164 (6.6)
Epirubicin 161 (10.0) 1 (0.2) 1 (0.1) 162 (6.5)
Docetaxel 128 (8.0) 17 (2.8) 2 (2.8) 19 (2.1) 147 (5.9)
Vincristine 99 (6.2) 2 (1.0) 2 (0.2) 101 (4.1)
Oxaliplatin 71 (4.4) 1 (1.4) 1 (0.1) 72 (2.9)
Capecitabine 40 (2.5) 14 (2.3) 4 (5.6) 18 (2.0) 58 (2.3)
Paclitaxel 51 (3.2) 1 (0.2) 3 (4.2) 4 (0.5) 55 (2.2)
Gemcitabine 12 (0.7) 34 (5.6) 2 (2.8) 36 (4.1) 48 (1.9)
Vinorelbine 14 (0.9) 23 (3.8) 7 (9.7) 30 (3.4) 44 (1.8)
Carboplatin 17 (1.1) 24 (3.9) 1 (1.4) 25 (2.8) 42 (1.7)
Triptorelin 32 (2.0) 5 (0.8) 2 (2.8) 7 (0.8) 39 (1.6)
Fulvestrant 19 (1.2) 10 (13.9) 10 (1.1) 29 (1.2)
Bendamustine 27 (1.7) 27 (1.1)
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during the study years, and these two categories are
therefore not included in Table 1.
During the study years, the total prevalence of use of
biological drugs for cancer treatment doubled from 0.9 (in
2010) to 1.8 (in 2014) per 1000 inhabitants, mostly due to
the increased use of small molecules (? 120.8%) rather
than mAbs (? 88.4%) (Fig. 1, Electronic Supplementary
Material Table S2).
Accordingly, the costs of the biological drugs for cancer
treatment rapidly grew during the study years in Messina
Province from €6.6 million in 2010 (n = 591) to
€13.6 million in 2014 (n = 1150), with a total expenditure
of around €50 million during the five observation years
(Fig. 2). Likewise, the number of different biological drugs
that were prescribed to the study population increased from
17 in 2010 to 21 in 2014 (data not shown).
In 2020, based on our predictions, the expenditure for
biological study drugs will grow to €25 million.
Assuming a 50% uptake for trastuzumab and rituximab
biosimilars, in 2020 a potential yearly saving of more
than €1 million may be achieved in the Messina Province
(Fig. 3). Even if the uptake of the two biosimilars peaked
at 20%, a yearly potential saving of more than €400,000
may still be achieved. On the other hand, wider uptake
(80%) may allow a yearly saving of around €1.7 million
(Fig. 3).
4 Discussion
To our knowledge, this is the first observational study
investigating the prevalence of use and the costs of bio-
logical drugs in oncology in a large area of Southern Italy
using administrative healthcare databases.
Our results showed a dramatic increase in biological
drug use in oncology, considering both mAbs and small
molecules. These data are in line with the National Report
on Medicines Use in Italy in 2015 [9], which described an
18.2% increase in mAb consumption (ATC I level: L) in
comparison with the previous year. There may be different
reasons to explain the increasing number of cancer patients
using biological drugs. In recent years, an increasing
number of biological drugs have been marketed in Italy, as
confirmed by the increasing number of different ATCs for
cancer treatment dispensed in Messina during the study
years (from 17 in 2010 to 21 in 2014; data not shown).
Furthermore, many biological drugs already approved for
cancer treatment gained an extension to their indications of
use, thus guaranteeing access to these innovative therapies
to a larger number of patients. We observed an increase in
the number of prevalent users over time, despite a decrease
in the proportion of incident users (from 61.4% in 2011 to
54.4% in 2014; data not shown). These results reflect a
growing number of patients taking biological drugs for a
Table 1 continued
Characteristic mAbs
(n = 1607)
Small molecules Total
(n = 2491)
TKIs
(n = 609)
Proteasome
inhibitors
(n = 203)
mTOR-i
(n = 72)
Total
(n = 884)
Fludarabine 25 (1.6) 25 (1.0)
Otherse 54 (3.4) 24 (3.9) 2 (1.0) 6 (8.3) 32 (3.6) 86 (3.5)
Data are given as n (%) unless otherwise specified
Patients (n = 8) who were dispensed two different drugs at the index date were excluded
Patients (n = 2) whose sex and age were not available were excluded
No users of fusion proteins or immunomodulatory agents could be identified during the study years, and these two biological drugs categories are
therefore not included
ID index date, mAb monoclonal antibodies, mTOR-i mammalian target of rapamycin inhibitors, Q1–Q3 interquartile range, TKIs tyrosine-kinase
inhibitors
aType of cancer refers to the last cancer diagnosis registered within 6 months prior to the first dispensing of the study drugs, during the study
period
bNeoplasms of lymphatic tissue include lymphosarcoma and reticulosarcoma, Hodgkin’s disease, and non-Hodgkin’s lymphoma
cOther neoplasms include neoplasms of peritoneum, eye, brain, thyroid, bones and connective tissue, genitourinary system, pancreas, respiratory
organs (other than lungs), skin, carcinomas in situ, monoclonal gammopathy, prostate, benign neoplasm, breast (males), bladder and kidney,
esophagus, stomach, duodenum, trachea, larynx, and nasal cavities, and neoplasms of unspecified nature
dChemotherapeutics were identified within 6 months prior to the first dispensing of the study drugs, during the study period
eOther chemotherapeutics include cisplatin, pemetrexed, vinblastine, temozolomide, bleomycin, dacarbarzine, methotrexate, etoposide, eribulin,
topotecan, azacitidine, cabazitaxel, mitoxantrone, tegafur, vindesine, and fotemustine
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Fig. 1 Prevalence of biological
drugs use for cancer treatment
per 1000 inhabitants, stratified
by calendar year. mAb
monoclonal antibodies, mTOR
mammalian target of
rapamycin, TKI tyrosine kinase
inhibitors
Fig. 2 Expenditure for the dispensing of biological drugs in oncology
in Messina Province in the years 2010–2014, stratified by calendar
year and type of biological drugs. mAb monoclonal antibodies,
mTOR-i mammalian target of rapamycin inhibitors, proteas-i protea-
some inhibitors, TKI tyrosine kinase inhibitors
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longer period of time, rather than an increase in those
initiating treatment. During the study years, no users of
fusion proteins or immunomodulatory agents could be
identified. Specifically, use of aflibercept has only been
approved in Sicily since November 2014 and we therefore
could not identify any users of this drug. Due to their costs,
many biological drugs in oncology are included among the
top 30 molecules for drug expenditure sustained by public
hospitals, with trastuzumab, bevacizumab, and rituximab
being the top three.
Rituximab lost its patent in 2013 and a biosimilar has
been available on the European market since 2017, while
biosimilars of trastuzumab and bevacizumab are currently
under review by the EMA and will probably enter the
market in the near future. In the USA, a bevacizumab
biosimilar was approved in September 2017 [10], ritux-
imab lost its patent in 2016 and the trastuzumab patent will
expire in 2019 [11].
The assumptions taken into account for the forecast
of the expected expenditure on biological drugs in oncol-
ogy until 2020 are as follows:
1. Biosimilars have been available on the European and
Italian market since 2006 and they guarantee a
20–30% lower cost than the reference product [12].
Such cost reductions may reach significantly higher
percentages when a larger uptake of biosimilars
occurs, as demonstrated in Norway with infliximab
[13]. When originally marketed in Italy, the
biosimilars were around 25% cheaper than the corre-
sponding reference products.
2. Biosimilar rituximab was marketed in Europe in 2017,
trastuzumab has lost its patent and the corresponding
biosimilar is under review by the EMA, while
bevacizumab will lose its patent in 2022, although its
biosimilar is already under review by the EMA [5, 14].
3. In recent years, several observational studies have
evaluated the uptake of biosimilars in different Italian
regions, highlighting a relevant heterogeneity across
geographic areas [15, 16]. Results showed that the
uptake of biosimilars ranged from 25 to 45% for
epoetins and from 25% to almost 90% for granulocyte
colony-stimulating factors, depending on the region
considered. This heterogeneity is likely to be due to
different healthcare policy interventions promoting the
use of the cheapest biological drug and to the
skepticism of clinicians regarding the effectiveness
and safety of biosimilars.
In 2016, a survey was conducted in Italy to explore
clinicians’ perceptions of biological drugs and biosimilars
[17]. Most of the interviewed clinicians (60%) were
rheumatologists, nephrologists, diabetologists, dermatolo-
gists, oncologists, gastroenterologists, and endocrinolo-
gists. Considering naı¨ve patients, 27% of those interviewed
usually prescribe an originator biological drug. Concerning
patients already receiving treatment with biological drugs,
19% of the clinicians switched the therapy due to non-
Fig. 3 Prevision of expenditure for biological drugs for cancer treatment in Messina area, assuming an uptake of trastuzumab and rituximab
biosimilars of 0, 20, 50, and 80%
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clinical reasons, i.e., to contribute to the sustainability of
the NHS or to respect specific healthcare policies pro-
moting the use of the cheapest biological drug. Only 28%
of those interviewed consider biosimilars to be as effective
and safe as the reference products.
In order to realistically predict expenditure, we assumed
a 25% reduction in the purchase costs of those biological
drugs for which the biosimilars are or will be available by
2020 (rituximab and trastuzumab). Considering the
observed variability in the uptake of biosimilars, we
hypothesized four different scenarios, assuming an uptake
equal to 0, 20, 50, or 80% of the total consumption of the
two biological drugs.
Assuming a 50% uptake of the biosimilars only for these
two anticancer biological drugs, a potential saving of at
least €1 million yearly in Messina Province was hypothe-
sized, thus representing an important strategy to mitigate
the constantly increasing expenditure for biological drugs
in cancer treatment. However, the predicted expenditure in
scenario n. 1 (Fig. 3) may be overestimated due to the
potential decrease in the cost of the reference products after
patent expiration. On the other hand, the future marketing
of innovative and highly priced biological drugs for the
treatment of cancer will likely increase pharmaceutical
expenditure. In addition, patients treated first with the study
biological drugs or with the corresponding biosimilars may
switch to newly marketed innovative drugs, thus leading to
an increase in total expenditure and to a lower uptake of
biosimilars.
Marketing of biosimilars in oncology may also help the
sustainability of NHSs while favoring access to medicines
that may in some cases have an extremely significant
impact on the clinical outcomes for cancer patients. In line
with this, ipilimumab, trastuzumab emtansine, pertuzumab,
and brentuximab vedotin have also been identified as
innovative drugs by the Italian Drug Agency in light of the
documented additional therapeutic value compared with
the available alternative treatments [18].
In such a context, post-marketing monitoring systems
using real-world data may allow rapid evaluations of the
uptake, appropriate use, safety, and economic impact of the
high-cost biological drugs and their corresponding
biosimilars in cancer patients, thus optimizing pharma-
ceutical expenditure. For most of the biological drugs
approved for cancer treatment, the Italian Drug Agency
implemented drug-specific monitoring registries as tools to
monitor the appropriate use, effectiveness, and safety of
those drugs that may facilitate post-marketing monitoring,
although so far these registries have not been systemati-
cally used for scientific purposes [19]. On the other hand,
an Italian network of claims databases has been success-
fully built for the post-marketing assessment of benefit–risk
profiles of biologics/biosimilars in other therapeutic areas,
thus demonstrating that these sources may also offer
greater opportunities for exploring the clinical and eco-
nomic impact of biological drugs and related biosimilars in
oncology in the real-world setting [15, 16, 20].
4.1 Strengths and Limitations
Using administrative healthcare databases, including dis-
pensing data and the hospital discharge diagnosis, this
observational study investigated the prevalence of use and
the costs of biological drugs in oncology in a large area
from Southern Italy, covering a population of more than
650,000 people. Using the dispensing databases of three
centers, we were able to capture all data regarding dis-
pensing of the study drugs to outpatients resident in the
Messina area. It is possible that patients resident in Messina
receive the study drugs outside the catchment area (i.e.,
choose to be treated in other areas of Sicily or in other
Italian regions), but this is unlikely. Due to the frequency
of administration, especially for infusion biological drugs,
patients are much more likely to choose the closest
oncology center.
As administrative databases do not include information
about the indication for use, it is possible that using the
diagnosis from the hospital discharge database may detect
a diagnosis that is not the main indication for which the
drug is used. To minimize the potential misclassification in
terms of the indication of use, we considered the last cancer
diagnosis within 6 months prior to the ID as the possible
indication of use.
5 Conclusion
The use of and corresponding expenditure relating to bio-
logical drugs for cancer treatment has rapidly and dra-
matically increased, almost doubling over a 5-year period
in a large general population of Southern Italy. Significant
uptake of biosimilars of trastuzumab and rituximab, which
will be available shortly on the European Union market,
may partly mitigate the pharmaceutical expenditure of
biological drugs in cancer patients. On the other hand, real-
world data are essential to rapidly monitor the benefit–risk
profile and appropriate use of biological drugs and related
biosimilars in routine care, with the final goal being to
optimize pharmaceutical expenditure in oncology patients.
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